2.
Götz I;
Grosu AL;
Spehl TS
Role of PET Imaging in Patients with High-Grade Gliomas undergoing anti-angiogenic Therapy with Bevacizumab – Review of the Literature and Case Report
Glioblastoma
European Association of NeuroOncology Magazine 2014; 4 (3): 102-108
Imaging results of a patient with glioblastoma undergoing bevacizumab
therapy. First column: MRI (MP-RAGE with contrast enhancement); second column:
18F-FET-PET (parametric images sc
aled to mean uptake in a right temporal reference
region); third column: image fusion. (A) scan prior to therapy 07/2010; (B) scan after
8 weeks of bevacizumab 09/2010; (C) scan after 16 weeks of bevacizumab 11/2010;
(D) scan after re-irradiation with 20 Gy, 01/2011. Bevacizumab therapy was continued.
For details, see text
Keywords:
Bevacizumab,
glioblastoma,
MRI